Conference preview: 12th Pharma & Biotech Patent Litigation

The event comes at a significant time for European IP, with political uncertainty and the current state of IP proving a series of challenges for pharmaceutical and biotech companies conducting business in Europe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

Pharma

What’s at stake in Australia’s biggest pharma patent appeal in years?

1 July 2026 Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.

Pharma

US life sciences damages averaged $33.5m between 2019-2025

18 June 2026 Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

More features

Influential Women in IP 2026: Who made the list?

WilmerHale trade secrets expert moves to new firm

UPC revives patent, but timing sinks Guardant’s appeal

LSD trade secrets suit over clinical trail info thrown out by judge

HGF expands European offering with pair of in-house hires

What’s at stake in Australia’s biggest pharma patent appeal in years?

Will Mounjaro and Zepbound get their first US generic rival?

Ashurst Perkins Coie opens its doors following landmark merger

Conference preview: 12th Pharma & Biotech Patent Litigation

More on this story

Editor's picks

Editor's picks

More features